Chudi Ndubaku

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Kelsey E. Sivick, Anthony L. Desbien, Laura Hix Glickman et al. · Cell Reports · 2018 · 417 citations · Full text

USP7 small-molecule inhibitors interfere with ubiquitin binding

Lorna Kategaya, Paola Di Lello, Lionel Rougé et al. · Nature · 2017 · 332 citations · Full text

Molecular Docking, Ubiquitin Binding, Drug Target +7

Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 328 citations · Full text

NK cells mediate clearance of CD8 ⁺ T cell–resistant tumors in response to STING agonists

Christopher J. Nicolai, Natalie K. Wolf, I-Chang Chang et al. · Science Immunology · 2020 · 249 citations · Full text

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Chudi Ndubaku, Timothy P. Heffron, Steven T. Staben et al. · Journal of Medicinal Chemistry · 2013 · 174 citations · Full text

Drug Target, Unbound Drug Exposure, Pharmacotherapy +21